Last reviewed · How we verify

Aspirin + Atorvastatin — Competitive Intelligence Brief

Aspirin + Atorvastatin (Aspirin + Atorvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent + HMG-CoA reductase inhibitor (statin). Area: Cardiovascular.

marketed Antiplatelet agent + HMG-CoA reductase inhibitor (statin) Cyclooxygenase (COX) + HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aspirin + Atorvastatin (Aspirin + Atorvastatin) — Fundacion GESICA. This combination reduces cardiovascular risk by inhibiting platelet aggregation (aspirin) and lowering LDL cholesterol (atorvastatin).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aspirin + Atorvastatin TARGET Aspirin + Atorvastatin Fundacion GESICA marketed Antiplatelet agent + HMG-CoA reductase inhibitor (statin) Cyclooxygenase (COX) + HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent + HMG-CoA reductase inhibitor (statin) class)

  1. Fundacion GESICA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aspirin + Atorvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-atorvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: